Coya Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a COYA research report →
Range $12 – $12
Price Chart
About the company
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies.
- CEO
- Arun Swaminathan
- IPO
- 2022
- Employees
- 8
- HQ
- Houston, TX, US
Get TickerSpark's AI analysis on COYA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $113.77M
- P/E
- -4.53
- PEG
- -0.42
- P/S
- 14.19
- P/B
- 0.00
- EV/EBITDA
- 1951.35
- Div Yield
- 0.00%
- Gross Margin
- 99.91%
- Op Margin
- -282.26%
- Net Margin
- -270.22%
- ROE
- -0.20%
- ROIC
- -0.05%
Latest fiscal year · YoY change
- Revenue
- $7.95M+123.6%
- Gross Profit
- $7.92M+195.3%
- Op Income
- $-20,265,623
- Net Income
- $-21,226,107-42.6%
- EPS
- $-1.27-29.6%
- OCF Growth
- -4.4%
- FCF Growth
- -4.4%
- 52W High
- $7.75
- 52W Low
- $3.71
- 50D MA
- $4.70
- 200D MA
- $4.73
- Beta
- 0.58
- RSI (14)
- 50
- Avg Volume
- 168.58K
No earnings-call transcripts are available for COYA yet.
- Free Float
- 85.3%
- Shares Outstanding
- 23.46M
- Float Shares
- 20.01M
of shares held by institutions
58 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Dme Capital Management, LP | 2.34M | 0 |
| Vanguard Group Inc | 899.14K | ▲ 62.75K |
| Vanguard Capital Management LLC | 842.22K | ▼ 2.69K |
| Alyeska Investment Group, L.P. | 800.00K | 0 |
| Aigh Capital Management LLC | 631.91K | ▼ 343.49K |
| Cm Management, LLC | 400.00K | ▲ 25.00K |
| Private Management Group Inc | 384.22K | ▲ 15.12K |
| Marshall Wace, Llp | 249.79K | ▲ 24.00K |
| Geode Capital Management, LLC | 228.24K | ▼ 5.16K |
| Renaissance Technologies LLC | 192.99K | ▲ 89.02K |
| Prosight Management, LP | 170.00K | ▼ 250.36K |
| Dimensional Fund Advisors LP | 155.92K | ▲ 60.00K |
Held by 34 ETFs
Biggest fund positions in COYA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 9, 26 | Pavao Mark H | other | 10,000 |
| Apr 1, 26 | Pavao Mark H | other | 0 |
| Jan 22, 26 | SNYDER DAVID S | other | 140,041 |
| Jan 22, 26 | Grossman Fred | other | 140,041 |
| Jan 22, 26 | Berman Howard | other | 15,257 |
| Jan 22, 26 | Swaminathan Arun | other | 293,983 |
| Jan 2, 26 | Villalobos Anabella | other | 10,000 |
| Jan 2, 26 | GOLDSTEIN DOV A MD | other | 10,000 |
| Jan 2, 26 | Weinand Dieter | other | 10,000 |
| Jan 2, 26 | ROSS WILBUR L JR | other | 10,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our COYA coverage
Recent articles, reports, and earnings notes.
No research on COYA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate COYA report →Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
businesswire.com · Oct 5
Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
businesswire.com · Sep 15
Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation
businesswire.com · Sep 8
Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
businesswire.com · Aug 11
Is Coya Therapeutics, Inc. (COYA) Stock Outpacing Its Medical Peers This Year?
zacks.com · Jun 30
Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting
gurufocus.com · Jun 18
Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting
businesswire.com · Jun 18
Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease
gurufocus.com · Jun 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.